Drug Trial Radar · NCT04599855
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
Last checked: Nov 20, 2026Latest source record: Apr 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
477
Actual
Start
Nov 4, 2020
Primary completion
Jan 31, 2024
Study completion Jan 31, 2024
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Oct 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of each individual dose of esketamine nasal spray, 56 milligram (mg) and 84 mg, compared with placebo nasal spray in improving depressive symptoms in participants with treatment resistant depression (TRD), as assessed by the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from Day 1 (prerandomization) to the end of the 4 week double-blind treatment phase (Day 28).
Conditions
- Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mgDrug
Esketamine 56 mg will be self administered as nasal spray.
Esketamine 84 mgDrug
Esketamine 84 mg will be self administered as nasal spray.
PlaceboDrug
Matching placebo will be self administered as nasal spray.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double-blind Treatment Phase: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Day 1 (Pre-randomization) to Day 28Time frame: Day 1 (pre-randomization) to Day 28 (end of DB treatment phase)
Locations
54 sites in 1 country. Site status is shown where the registry gives one.
UAB Department of Psychiatry and Behavioral Neurobiology
Birmingham, Alabama
UAB Huntsville Regional Medical Campus
Huntsville, Alabama
Preferred Research Partners
Little Rock, Arkansas
Behavioral Research Specialists LLC
Glendale, California
CalNeuro Research
Los Angeles, California
Pacific Research Partners
Oakland, California
Anderson Clinical Research
Redlands, California
University of California at San Diego
San Diego, California
Artemis Institute for Clinical Research
San Diego, California
UCSF Nancy Friend Pritzker Psychiatry Building
San Francisco, California
Velocity Clinical Research
Santa Ana, California
CMB Clinical Trials
Santee, California
University of Connecticut Health Center
Farmington, Connecticut
Velocity Clinical Research, Hallandale Beach
Hallandale, Florida
Accel Research Sites
Lakeland, Florida
APG Research LLC
Orlando, Florida
USF, Department of Psychiatry and Behavioral Neurosciences
Tampa, Florida
Neuroscience Research Institute
West Palm Beach, Florida
Atlanta Behavioral Research, LLC
Atlanta, Georgia
Psych Atlanta, P.C.
Marietta, Georgia
Rush University Medical Center
Chicago, Illinois
Chicago Research Center
Chicago, Illinois
University of Chicago
Chicago, Illinois
Joliet Center for Clinical Research
Joliet, Illinois
Pillar Clinical Research, LLC
Lincolnwood, Illinois
Psychiatric Medicine Associates LLC
Skokie, Illinois
Ascension via Christi Research
Wichita, Kansas
University of Kansas School of Medicine
Wichita, Kansas
Sheppard Pratt Health System
Baltimore, Maryland
CBH Health
Gaithersburg, Maryland
Copley Clinical
Boston, Massachusetts
Adams Clinical
Watertown, Massachusetts
University of Massachusetts Medical School
Worcester, Massachusetts
University of Michigan
Ann Arbor, Michigan
Rochester Center for Behavioral Medicine (RCBM)
Rochester Hills, Michigan
Midwest Research Group - St. Charles Psychiatric Associates
Saint Charles, Missouri
Clinilabs
New York, New York
The Medical Research Network, LLC
New York, New York
Stony Brook University Medical Center
Stony Brook, New York
Ohio State University
Columbus, Ohio
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.